U.S. Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025

Description

U.S. contraceptives market was estimated at USD 7.3 billion in 2024 and is expected to grow from USD 7.6 billion in 2025 to USD 13.5 billion by 2034, at a CAGR of 6.6%, according to the latest report published by Global Market Insights Inc.

Public health campaigns and educational programs have significantly increased awareness about the importance of birth control and reproductive autonomy, leading to greater adoption of contraceptives across age groups.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$7.3 Billion
Forecast Value	$13.5 Billion
CAGR	6.6%

Devices to Gain Traction

The devices segment held a significant share in 2024, driven largely by the growing preference for long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and contraceptive implants. These methods offer years of protection with minimal user intervention, making them ideal for individuals seeking low-maintenance and highly effective birth control. Healthcare providers recommend device-based options over daily-use products.

Rising Prevalence Among 15-44 Years

The individuals aged 15 to 44 segment held sustainable growth in 2024, driven by most of the demand across both prescription and over-the-counter categories. This age group encompasses teens, young adults, and women in their reproductive prime, making it a key focus for public health campaigns and commercial marketing efforts alike.

Increasing Demand in Retail Pharmacies

The retail pharmacies segment held a notable share in 2024, backed by offering consumers convenient access to prescription and over-the-counter products. Chains like CVS, Walgreens, and independent stores serve as primary points of sale for birth control pills, condoms, emergency contraceptives, and even telehealth-related fulfillment. In-store education campaigns, loyalty programs, and discreet purchasing options continue to make pharmacies a trusted channel for contraceptive access.

Regional Insights

South Atlantic to Emerge as a Lucrative Region

South Atlantic contraceptives market held a sustainable share in 2024, driven by a combination of rising population density, urbanization, and expanded access to reproductive health services. Although the region faces ongoing disparities in care access, particularly in rural areas telehealth expansion and mobile clinics are helping bridge gaps. Ongoing public health initiatives and targeted education efforts are also helping normalize contraceptive use across diverse communities.

Major players in the U.S. Contraceptives Market are Evofem Biosciences, Reckitt, Mayer Laboratories, Perrigo Company, Johnson & Johnson, Organon, Pregna International, Church & Dwight, LifeStyles Healthcare, Agile Therapeutics, CooperSurgical, Pfizer, Meril Life Sciences, Bayer, and HRA Pharma.

Companies in the U.S. contraceptives market are strengthening their foothold through a blend of product innovation, targeted awareness campaigns, and expanded distribution channels. Many are investing in the development of hormone-free alternatives, biodegradable condoms, and extended-release devices to meet evolving consumer preferences. Strategic partnerships with telehealth platforms and pharmacy chains are also helping brands reach customers more directly and discreetly. Additionally, companies are leveraging data analytics to personalize marketing, focusing on segments such as first-time users, post-partum women, and college students.

Product Code: 11769

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Data mining sources
1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
1.5 Primary research and validation
- 1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis
2.2 Key market trends
- 2.2.1 Zonal trends
- 2.2.2 Product trends
- 2.2.3 Age group trends
- 2.2.4 Distribution channel trends
2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Favourable regulatory scenario in developed nations
  - 3.2.1.2 Growing inclination towards planned delayed pregnancy
  - 3.2.1.3 Growing use of modern contraceptives
  - 3.2.1.4 Increasing prevalence of sexually transmitted diseases (STD)
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Adverse effects of contraceptive drugs
- 3.2.3 Market opportunities
  - 3.2.3.1 Growth in demand for long-acting reversible contraceptives (LARCs)
  - 3.2.3.2 Rising trend of non-hormonal and natural contraceptive alternatives
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
3.6 Pricing analysis, 2024
3.7 Consumer behaviour analysis
3.8 U.S. supply chain dynamics and domestic manufacturing trends
3.9 Brand analysis
3.10 Business model of top companies
- 3.10.1 CooperSurgical
- 3.10.2 Reckitt
3.11 Go-to-Market strategy analysis
3.12 Gap analysis
3.13 Porter's analysis
3.14 PESTEL analysis
3.15 Future market trends
3.16 Value chain analysis
3.17 E-commerce and telehealth expansion: Overview
3.18 Impact of affordable care act (ACA) and insurance coverage on Contraceptive access

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Competitive analysis of major market players
4.6 Key developments
- 4.6.1 Mergers and acquisitions
- 4.6.2 Partnerships and collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Devices
- 5.2.1 Condoms
  - 5.2.1.1 Male
  - 5.2.1.2 Female
- 5.2.2 Intra-uterine devices
  - 5.2.2.1 Hormonal IUD
  - 5.2.2.2 Copper IUD
- 5.2.3 Vaginal rings
- 5.2.4 Subdermal implants
- 5.2.5 Diaphragms
- 5.2.6 Contraceptive sponges
5.3 Drugs
- 5.3.1 Oral contraceptive pills
- 5.3.2 Injectable contraceptives
- 5.3.3 Topical contraceptives

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 15 - 44 years
6.3 Above 44 years

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Retail pharmacies
7.3 Hospital pharmacies
7.4 Online channels
7.5 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Zone, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 Zones
- 8.2.1 East North Central
  - 8.2.1.1 Illinois
  - 8.2.1.2 Indiana
  - 8.2.1.3 Michigan
  - 8.2.1.4 Ohio
  - 8.2.1.5 Wisconsin
- 8.2.2 West South Central
  - 8.2.2.1 Arkansas
  - 8.2.2.2 Louisiana
  - 8.2.2.3 Oklahoma
  - 8.2.2.4 Texas
- 8.2.3 South Atlantic
  - 8.2.3.1 Delaware
  - 8.2.3.2 Florida
  - 8.2.3.3 Georgia
  - 8.2.3.4 Maryland
  - 8.2.3.5 North Carolina
  - 8.2.3.6 South Carolina
  - 8.2.3.7 Virginia
  - 8.2.3.8 West Virginia
  - 8.2.3.9 Washington, D.C.
- 8.2.4 Northeast
  - 8.2.4.1 Connecticut
  - 8.2.4.2 Maine
  - 8.2.4.3 Massachusetts
  - 8.2.4.4 New Hampshire
  - 8.2.4.5 Rhode Island
  - 8.2.4.6 Vermont
  - 8.2.4.7 New Jersey
  - 8.2.4.8 New York
  - 8.2.4.9 Pennsylvania
- 8.2.5 East South Central
  - 8.2.5.1 Alabama
  - 8.2.5.2 Kentucky
  - 8.2.5.3 Mississippi
  - 8.2.5.4 Tennessee
- 8.2.6 West North Central
  - 8.2.6.1 Iowa
  - 8.2.6.2 Kansas
  - 8.2.6.3 Minnesota
  - 8.2.6.4 Missouri
  - 8.2.6.5 Nebraska
  - 8.2.6.6 North Dakota
  - 8.2.6.7 South Dakota
- 8.2.7 Pacific Central
  - 8.2.7.1 Alaska
  - 8.2.7.2 California
  - 8.2.7.3 Hawaii
  - 8.2.7.4 Oregon
  - 8.2.7.5 Washington
- 8.2.8 Mountain States
  - 8.2.8.1 Arizona
  - 8.2.8.2 Colorado
  - 8.2.8.3 Utah
  - 8.2.8.4 Nevada
  - 8.2.8.5 New Mexico
  - 8.2.8.6 Idaho
  - 8.2.8.7 Montana
  - 8.2.8.8 Wyoming

Chapter 9 Company Profiles

9.1 Agile Therapeutics
9.2 Bayer
9.3 Church & Dwight
9.4 CooperSurgical
9.5 Evofem Biosciences
9.6 HRA Pharma / Perrigo (OTC)
9.7 Johnson & Johnson
9.8 LifeStyles Healthcare
9.9 Mayer Laboratories
9.10 Meril Life Sciences
9.11 Organon
9.12 Perrigo Company
9.13 Pfizer
9.14 Pregna International
9.15 Reckitt

U.S. Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034